


## CLAIMS

1. A vascular intimal hyperplasia inhibitor containing a 3(2H)-pyridazinone compound represented by the formula (I) or a pharmacologically acceptable salt thereof:

5



10

wherein each of  $R^1$ ,  $R^2$  and  $R^3$  is independently a hydrogen atom or a  $C_{1-6}$  alkyl group, X is a halogen atom, cyano or a hydrogen atom, Y is a halogen atom, trifluoromethyl or a hydrogen atom, and A is a  $C_{1-8}$  alkylene which may be substituted with a hydroxyl group.

2. The vascular intimal hyperplasia inhibitor according to Claim 1, wherein the compound represented by the formula (I) is one wherein in the formula (I),  $R^1$  and  $R^2$  are hydrogen atoms,  $R^3$  is a hydrogen atom or a  $C_{1-4}$  alkyl group, X is a halogen atom, Y is a halogen atom or a hydrogen atom, and A is a  $C_{1-5}$  alkylene which may be substituted with a hydroxyl group.

3. The vascular intimal hyperplasia inhibitor according to Claim 1, wherein the compound represented by the formula (I) is 4-bromo-6-[3-(4-chlorophenyl)propoxy]-5-

25

(3-pyridylmethylamino)-3(2H)-pyridazinone or 4-bromo-6-[3-(4-chlorophenyl)-3-hydroxypropoxy]-5-(3-pyridylmethylamino)-3(2H)-pyridazinone.

4. The vascular intimal hyperplasia inhibitor according  
5 to Claim 1, 2 or 3, wherein the pharmacologically acceptable salt is an organic acid salt or an inorganic acid salt.

5. The vascular intimal hyperplasia inhibitor according  
to Claim 1, 2 or 3, wherein the pharmacologically  
10 acceptable salt is a hydrochloride.